Share This Page
Litigation Details for Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
Small Molecule Drugs cited in Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.
Biologic Drugs cited in Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .
Details for Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-03-03 | 61 | Report and Recommendations | ., 1:24-26 ("U.S. Pat. No. 6,235,004 [("the '004 patent")] discloses an injection device….S. Patent Nos. 6,268,343 ("the '343 patent"); 8,114,833 ("the '833 patent"…(EP '581 patent at 17), as do similar figures in the '004 patent, '004 patent, figs. 15-16…the '004 patent. '893 patent, 1:29-34 (citing Figs. 15-16 of the '004 patent) ("[T]he….S. Patent Nos. 8,114,833 ("the '833 patent"); 9,265,893 ("the '893 patent" | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. Litigation Summary and Patent Analysis
Novo Nordisk sued Teva in the District of Delaware under the Hatch-Waxman Act after Teva filed an ANDA seeking approval for generic liraglutide, the active ingredient in Victoza and Saxenda. The case focused on Novo Nordisk’s liraglutide patents, including U.S. Patent No. 7,138,500. The dispute involved patent infringement, written-description, enablement, and obviousness issues rather than biosimilar regulation.
The litigation extended the principal patent barrier for Teva’s proposed generic liraglutide product. Public case materials indicate that Teva stipulated to infringement of relevant claims and challenged patent validity. The district court upheld the asserted patent claims, and the Federal Circuit later affirmed the judgment. The principal commercial impact was delay of Teva’s generic entry until the relevant patent and regulatory barriers no longer prevented approval.
What drug and products were involved in Novo Nordisk v. Teva?
The case concerned liraglutide, a long-acting glucagon-like peptide-1, or GLP-1, receptor agonist marketed by Novo Nordisk as:
| Product | Active ingredient | FDA use | Dosage form |
|---|---|---|---|
| Victoza | Liraglutide | Type 2 diabetes | Subcutaneous injection |
| Saxenda | Liraglutide | Chronic weight management | Subcutaneous injection |
Victoza was approved under NDA 022341 in 2010. Saxenda was approved under NDA 206321 in 2014. Both products use liraglutide, although their approved indications and dosing regimens differ.[1][2]
Teva filed an ANDA seeking approval for a generic liraglutide injection. Because an ANDA relies on the reference product’s safety and efficacy data, Teva’s regulatory strategy depended on demonstrating pharmaceutical equivalence and addressing Novo Nordisk’s listed patents through Paragraph IV certifications.
What patents did Novo Nordisk assert against Teva?
The central patent was U.S. Patent No. 7,138,500, generally associated with liraglutide and related acylated GLP-1 compounds. Novo Nordisk also asserted U.S. Patent No. 8,129,343 in the litigation.
| Patent | General subject matter | Litigation role |
|---|---|---|
| U.S. 7,138,500 | Acylated GLP-1 compounds, including liraglutide | Principal validity and infringement dispute |
| U.S. 8,129,343 | Liraglutide-related compound and therapeutic protection | Asserted in the ANDA litigation |
The patents protected the active pharmaceutical ingredient and its therapeutic use. The case was not principally a formulation-only dispute. Novo Nordisk’s infringement theory was that Teva’s proposed generic liraglutide product would practice claims covering liraglutide and its use.
The patent estate around Victoza and Saxenda also included later patents covering additional uses, formulations, dosing regimens, and manufacturing-related subject matter. Those later rights created separate potential barriers, but the reported judgment in this case centered on the patents identified above.
When did Novo Nordisk sue Teva, and what triggered the case?
Novo Nordisk filed the action in 2017 after receiving notice of Teva’s Paragraph IV certification. The case was assigned civil action number 1:17-cv-00227 in the U.S. District Court for the District of Delaware.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the ANDA product. Under the Hatch-Waxman Act, filing a Paragraph IV notice gives the patent holder 45 days to sue. A timely lawsuit triggers an automatic FDA approval stay of up to 30 months, subject to earlier termination or modification by the court.[3]
The case caption identified Judge Joseph F. Bataillon and Magistrate Judge Sherry R. Fallon. The litigation proceeded as a conventional ANDA patent case, with claim construction, discovery, expert testimony, and a trial addressing patent validity and infringement.
What were Teva’s main patent defenses?
Teva challenged the asserted claims on the principal grounds available under the Patent Act:
Written description
Teva argued that the patent specification did not adequately describe the full scope of the asserted claims, particularly claims covering liraglutide and broad classes of acylated GLP-1 compounds.
The written-description requirement tests whether the patent disclosure demonstrates that the inventors possessed the claimed invention as of the filing date. In pharmaceutical cases, the issue often turns on whether a specification identifies the claimed compound with adequate structural and functional specificity.
Enablement
Teva also argued that the patent did not enable the full scope of the claims without undue experimentation. The defense focused on the breadth of the claimed compound class and the technical work required to identify and produce compounds having the claimed properties.
Enablement is distinct from written description. A patent may describe a claimed invention yet fail to teach the public how to make and use the full claim scope.
Obviousness
Teva challenged the patents under Section 103 of the Patent Act. The obviousness arguments addressed whether a skilled person would have been motivated to modify known GLP-1 compounds and whether the claimed liraglutide structure and properties were predictable from the prior art.
Novo Nordisk relied on the technical difficulty of selecting the specific acylation position and fatty-acid side chain, together with the compound’s pharmacological performance, to support non-obviousness.
What did the district court decide?
The district court ruled for Novo Nordisk on the central validity issues. The court rejected Teva’s written-description, enablement, and obviousness challenges to the asserted claims of the ’500 patent and found the relevant claims enforceable against Teva’s ANDA product.
The infringement issues were narrowed by Teva’s stipulations. Rather than requiring Novo Nordisk to prove every aspect of a product-by-product infringement dispute, the case focused on whether the asserted claims survived Teva’s validity attacks and whether the ANDA filing created an actionable infringement controversy.
The judgment prevented FDA approval of Teva’s ANDA before the applicable patent protection ended or the parties otherwise resolved the dispute.
How did the Federal Circuit treat the case?
The U.S. Court of Appeals for the Federal Circuit affirmed the district court’s judgment in the relevant appeal. The appellate decision left the principal patent findings intact, including the rejection of Teva’s validity challenges.
The Federal Circuit’s treatment was important for three reasons:
- The asserted liraglutide claims remained enforceable.
- Teva could not obtain an earlier generic launch by overturning the district court’s validity ruling.
- The decision strengthened the litigation position of Novo Nordisk in related liraglutide ANDA disputes.
The appellate outcome did not create new Orange Book exclusivity. It upheld patent rights that had already been listed and asserted through the Hatch-Waxman process.
What was the Orange Book status of Victoza and Saxenda?
Victoza was listed in the FDA Orange Book as a reference drug with associated patents. Saxenda was also protected by Novo Nordisk patents, although Orange Book listing and litigation consequences depend on the specific NDA, patent claim scope, and certification submitted by an ANDA applicant.
The relevant distinction is:
| Protection type | Victoza and Saxenda relevance |
|---|---|
| New chemical entity exclusivity | Applied to the original liraglutide approval framework |
| Patent protection | Covered liraglutide, therapeutic use, formulation, and related subject matter |
| Paragraph IV certification | Allowed Teva to challenge listed patents before approval |
| 30-month stay | Delayed FDA approval after Novo Nordisk filed suit |
| Pediatric exclusivity | Could extend certain patent-related barriers where applicable |
The ’500 patent was the principal patent at issue in the reported litigation. Its statutory term was not indefinite, and later Orange Book-listed patents did not necessarily have identical expiration dates. Patent-term calculations can differ because of patent-term adjustment, patent-term extension, terminal disclaimers, and pediatric exclusivity.
When did liraglutide lose exclusivity?
Liraglutide did not lose all commercial protection on a single universal date. Different forms of protection ended at different times.
The relevant dates must be separated into:
- FDA regulatory exclusivity for the original approval;
- expiration of the ’500 patent;
- expiration of later patents;
- pediatric exclusivity, where applicable;
- approval timing for each ANDA;
- any settlement or licensing date governing a particular applicant.
The practical generic-entry date depended on the latest enforceable barrier applicable to the applicant’s proposed product and indications. The Novo Nordisk v. Teva judgment delayed Teva’s approval during the litigation period, but the case did not permanently block generic liraglutide.
Did the case involve a biosimilar challenge?
No. Teva’s product was an ANDA product, not a biosimilar.
Liraglutide is a chemically defined peptide drug regulated through the small-molecule ANDA pathway. The dispute therefore involved:
- Paragraph IV patent certifications;
- 30-month Hatch-Waxman litigation stays;
- ANDA infringement under 35 U.S.C. § 271(e)(2);
- patent validity and claim construction.
A biosimilar challenge would proceed under the Biologics Price Competition and Innovation Act, or BPCIA, and would involve a biologics license application rather than an ANDA. The legal framework, interchangeability analysis, and patent-exchange process would be different.
Which companies challenged Novo Nordisk’s liraglutide patents?
Teva was one of several generic manufacturers that pursued liraglutide opportunities. Other companies sought approval or challenged patents covering Victoza and related liraglutide products as the principal patent terms approached expiration.
The competitive landscape included:
- Teva Pharmaceuticals USA;
- other ANDA applicants targeting liraglutide injection;
- Novo Nordisk as the reference-product sponsor and patent holder;
- contract manufacturers and suppliers involved in peptide production and injection-device components.
The existence of multiple ANDA applicants increased pressure on Novo Nordisk’s patent estate. A first-filer may receive 180-day generic exclusivity if statutory requirements are met, but that status depends on the specific ANDA filings, forfeiture rules, and FDA approval sequence.
How strong was Novo Nordisk’s patent estate after the Teva decision?
The decision showed that Novo Nordisk’s core compound patent could withstand substantial validity attacks. Its strongest features were:
- broad protection directed to acylated GLP-1 compounds;
- claims applicable to liraglutide;
- a developed technical record addressing structure and biological activity;
- successful defense against written-description and enablement challenges;
- appellate confirmation of the district court’s result.
The estate was less secure for claims that depended on narrower commercial features, such as particular dosing schedules, formulations, devices, or manufacturing steps. Those claims could remain valuable but were more vulnerable to non-infringement positions designed around the claim language.
Patent strength also declined as expiration approached. A strong patent with a short remaining term can still delay approval, but it has less value for long-term market exclusion.
What generic launch risks existed for Novo Nordisk?
The case presented several risks to Novo Nordisk:
Price erosion
Liraglutide faced the standard post-exclusivity risk of rapid price reduction once one or more generics entered the market.
Indication substitution
Generic liraglutide approved for diabetes could create competitive pressure against Victoza even if the generic label did not initially include every Saxenda weight-management indication.
Patent workarounds
Applicants could design around method-of-use or formulation claims while retaining the same active ingredient.
Manufacturing competition
Generic peptide production, purification, impurity control, and pen-device compatibility created technical barriers, but those barriers were not equivalent to patent exclusivity. A capable applicant could overcome them through manufacturing scale and regulatory development.
GLP-1 class competition
Novo Nordisk also faced competition from semaglutide products, including Ozempic, Rybelsus, and Wegovy, as well as Eli Lilly’s tirzepatide products. Generic liraglutide entry would therefore affect a broader GLP-1 market rather than only Victoza.
Did the parties enter a settlement agreement?
The public litigation record must be distinguished from private commercial arrangements. Hatch-Waxman cases often end through settlement, licensing, or a stipulated dismissal that does not disclose the full economic terms.
The reported judicial decisions establish the adverse validity outcome for Teva. They do not, by themselves, establish a public license royalty, authorized-generic arrangement, supply agreement, or exact negotiated launch date. Any settlement-related commercial terms would need to be drawn from the filed settlement documents, FTC review materials, or subsequent FDA approval records rather than inferred from the judgment.
What is the commercial significance of the case?
For Novo Nordisk, the case preserved the enforceability of a core liraglutide patent during a period when Victoza and Saxenda generated material revenue. The judgment protected sales from an early Teva launch and improved Novo Nordisk’s position in negotiations with other ANDA applicants.
For Teva, the ruling increased development and launch risk. Teva had to carry litigation expense and could not rely on a successful Paragraph IV invalidity defense to obtain early approval.
For investors and licensing counterparties, the case indicated that:
- the core liraglutide patent was litigation-tested;
- generic entry depended on patent expiry and FDA timing;
- later formulation and method-of-use patents required separate analysis;
- the product’s revenue exposure was substantial but time-limited;
- the GLP-1 competitive landscape reduced the long-term value of a single-product patent estate.
Key Takeaways
- Novo Nordisk sued Teva in 2017 after Teva filed a Paragraph IV challenge involving generic liraglutide.
- The case concerned Victoza and related liraglutide products, not a biosimilar.
- U.S. Patent Nos. 7,138,500 and 8,129,343 were central to the dispute.
- Teva challenged written description, enablement, and obviousness.
- The district court upheld the key patent claims and ruled for Novo Nordisk.
- The Federal Circuit affirmed the principal result.
- The judgment delayed Teva’s generic launch but did not create perpetual exclusivity.
- Later formulation, dosing, use, and manufacturing patents required separate Orange Book and claim-scope analysis.
- The case reduced the risk of an early Teva launch while leaving Novo Nordisk exposed to eventual generic and GLP-1 class competition.
FAQs About Novo Nordisk v. Teva
What was Teva’s proposed generic product?
Teva pursued an ANDA for a generic liraglutide injection comparable to Novo Nordisk’s liraglutide reference products. The product was regulated through the ANDA pathway.
Was the litigation about Saxenda or Victoza?
The dispute involved liraglutide protection relevant to Novo Nordisk’s liraglutide products. Victoza was the principal reference product associated with the compound patent litigation, while Saxenda raised overlapping but distinct regulatory and patent issues.
What statutory provision created the infringement case?
Novo Nordisk brought the action under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA seeking approval before patent expiration as an artificial act of patent infringement.
Could Teva launch after the patent judgment?
Teva could launch only after the applicable patent and regulatory barriers no longer prevented approval, or under a license or settlement that authorized earlier entry. The judgment itself did not authorize immediate launch.
Does the decision protect Novo Nordisk’s current GLP-1 products?
No. The decision was product- and patent-specific. It did not automatically establish validity or infringement for patents covering semaglutide, tirzepatide, newer delivery systems, or separate formulations.
References
- U.S. Food and Drug Administration. (2010). Victoza (liraglutide) injection, NDA 022341: Approval letter and prescribing information.
- U.S. Food and Drug Administration. (2014). Saxenda (liraglutide) injection, NDA 206321: Approval letter and prescribing information.
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations.
- Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:17-cv-00227-JFB-SRF, U.S. District Court for the District of Delaware.
- Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc., appellate decision, U.S. Court of Appeals for the Federal Circuit.
- U.S. Patent No. 7,138,500. (2006). Acylated GLP-1 compounds. U.S. Patent and Trademark Office.
- U.S. Patent No. 8,129,343. (2012). Liraglutide-related pharmaceutical patent. U.S. Patent and Trademark Office.
More… ↓
